The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients

Scandinavian Journal of Rheumatology

Volumn 44, Issue 4, 2015, Pages 271-279

  Nagel, J ^a   Geborek, P ^a   Saxne, T ^a   Jonsson G ^a   Englund, M ^b,c   Petersson, I F ^b   Nilsson, J A ^a   Kapetanovic, M C ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; ANTIRHEUMATIC AGENT; VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; ICD-10; IMMUNIZATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTPATIENT CARE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SPONDYLOARTHROPATHY; SURVIVAL; VACCINATION; AGED; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; COMPLICATION; FOLLOW UP; IMMUNOLOGY; PNEUMOCOCCAL INFECTIONS; SPONDYLARTHROPATHIES; SWEDEN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK FACTORS; SPONDYLARTHROPATHIES; SWEDEN; VACCINES, CONJUGATE;

EID: 84937792485     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.984754     Document Type: Article

References (48)

1. Pneumococcal vaccines.WHOposition paper 2012, vol. 87, pp. 129-144. Available at: www.who.int/wer/2012.
2. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices. Available at: http://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html.
3. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infections in patients with rheumatoid arthritis compared with controls. Arthritis Rheum 2002;46:2287-93.
4. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012;66:1177-81.
5. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Rheum Dis 2011;70:1921-5.
6. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64:1035-50.
7. Ni Mhuircheartaigh OM, Matteson EL, Green AB, Crowson CS. Trends in serious infections in rheumatoid arthritis. J Rheumatol 2013;40:611-16.
8. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
9. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52:53-61.
10. Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract 2009;59:e329-38.
11. Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, at al. Vaccinations in patients with immunemediated inflammatory diseases. Rheumatology (Oxford) 2010;49:1815-27.
12. Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without TNF-blockers: a systematic review and metaanalysis of randomised placebo-controlled trials. Ann Rheum Dis 2010;69:1756-61.
13. Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL. Development and validation of a risk score for serious infections in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64:2847-55.
14. Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, et al. Current evidence for the management of rheumatic arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.
15. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86.
16. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
17. Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012;12:225-9.
18. Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:1125-34.
19. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a metaanalysis. CMAJ 2009;180:48-58.
20. Assaad U, El-Masri I, Porhomayon J, El-Solh AA. Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging 2012;7:453-61.
21. Cadeddu C, De Waure C, Gualano MR, Di Nardo F, Ricciardi W. 23-Valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: is it really effective? J Prev Med Hyg 2012;53:101-3.
22. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013;1:CD000422.
23. Centers for Disease Control. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000:49(RR09);1-38.
24. Robinson K, Baughman W, Rothrock G, Rothrock G, Barrett NL, Pass M, et al. Epidemiology of Streptococcus pneumoniae infections in the U.S., 1995-1998: opportunities for prevention in the conjugate vaccine era. J Am Med Assoc 2001; 285:1729-35.
25. Foster D, Walker AS, Paul J, Griffiths D, Knox K, Peto TE, et al. Oxford Invasive Pneumococcal Surveillance Group. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol 2011;60:91-7.
26. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after sevenvalent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11:760-8.
27. Arguedas A, Soley C, Abdelnour A. Prevenar experience. Vaccine 2011;29(Suppl 3):C26-34.
28. McIntosh ED, Conway P, Willingham J, Hollingsworth R, Lloyd A. Pneumococcal pneumonia in the UK-how herd immunity effects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 200523;1739-45.
29. Hanage WP, Bishop CJ, Huang SS, Stevenson AE, Pelton SI, Lipsitch M, et al. Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching. Pediatr Infect Dis J 2001;30:302-8.
30. Millar EV, Pimenta FC, Roundtree A, Jackson D, Carvalho Mda G, Perilla MJ, et al. Pre-and post-conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin Infect Dis 2010;51:1258-65.
31. Tocheva AS, Jefferies JM, Christodoulides M, Faust SN, Clarke SC. Increase in serotype 6C pneumococcal carriage, United Kingdom. Emerg Infec Dis 2010;16:154-5.
32. Tocheva AS, Jefferies JM, Rubery H, Bennett J, Afimeke G, Garland J, et al. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine 2011;29:4400-4.
33. Icardi G, Sticchi L, Bagnasco A, Iudici R, Durando P. Pneumococcal vaccination in adults: rationale, state of the art and perspectives. J Prev Med Hyg 2012;53:78-84.
34. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Autoimmun Rev 2011;10:341-52.
35. Pneumococcal vaccination: recommendations of the Swedish National Board of Health and Welfare [in Swedish]. SOSFS 1994:26 (M). Available at: http://www.socialstyrelsen.se/publikationer1994/1994-10-26.
36. Coulson E, Saravanan V, Hamilton J, So KL, Morgan L, Heycock C, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011;70:1289-91.
37. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:106-11.
38. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Methotrexate but not TNF-blockers reduces antibody response following pneumococcal vaccination using 7-valent conjugate pneumococcal vaccine in adult patients with established arthritis. Arthritis Rheum 2011;63:3723-32.
39. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology 2010;49:1563-9.
40. Haglund E, Bremander AB, Petersson IF, Strömbeck B, Bergman S, Jacobsson LT, et al. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis 2011;70:943-8.
41. Neovius M, Simard JF, Askling J; ARTIS Study Group. Nationwide prevalence of rheumatoid arthritis and penetration of diseasemodifying drugs in Sweden. Ann Rheum Dis 2011;70:624-9.
42. Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N, et al. ARTIS Study Group. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 2011;40:8-15.
43. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
44. [Swedish National Board of Health and Welfare. Database of inpatient diagnosis], in Swedish. Available at: www. socialstyrelsen.se/statistik/statistikdatabas/diagnoserislutenvard.
45. Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 201359;778-88.
46. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol 2011; 30:1555-61.
47. Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther 2013;15:R1.
48. Health Consumer Powerhouse 2008. Vaccinations index 2008 [in Swedish]. Available at: www.healthpowerhouse.se/hcp/apps/hcp/docs/RapportVaccinationsindex08finalfinal2.pdf.